Refine my results

Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma

Piguet, Anne-Christine ; Saar, Bettina ; Hlushchuk, Ruslan ; St-Pierre, Marie V. ; McSheehy, Paul M. ; Radojevic, Vesna ; Afthinos, Maresa ; Terracciano, Luigi ; Djonov, Valentin ; Dufour, Jean-François

In: Molecular Cancer Therapeutics, 2011, vol. 10, no. 6, p. 1007-1017

Sorafenib targets the Raf/mitogen activated protein kinase, VEGF and PDGF pathways and prolongs survival patients in advanced hepatocellular carcinoma (HCC). Everolimus inhibits the mammalian target of rapamycin, a kinase overactive in HCC. To investigate whether the antitumor effects of these agents are additive, we compared a combined and sequential treatment regimen of everolimus and...